Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc. operates as a pharmaceutical company primarily focused on developing and commercializing medications designed to manage elevated low-density lipoprotein (LDL) cholesterol levels in patients. Its flagship pharmaceutical products include NEXLETOL (bempedoic acid) and NEXLIZET (a combination of bempedoic acid and ezetimibe) in tablet form. These treatments are prescribed for individuals suffering from atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH). Additionally, Esperion has established strategic licensing and collaborative partnerships with Daiichi Sankyo Europe GmbH and Serometrix to obtain rights to an oral, small molecule PCSK9 inhibitor program. The company was founded in 2008 and its principal offices are located in Ann Arbor, Michigan.